CSTL
Castle Biosciences, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$32.91
+0.80%Jul 30, 2026, 22:06 UTC
Castle Biosciences reported second-quarter 2026 revenue of $103.5 million, up 20% year-over-year.
Jul 14, 2026, 20:30 UTC
Castle Biosciences received assay approval from the New York State Department of Health for its AdvanceAD-Tx test.
Source:Jun 16, 2026, 11:00 UTC
Castle Biosciences' TissueCypher Barrett's Esophagus Test surpassed 100,000 clinical test orders.